Engineered Extracellular Vesicles: Emerging Therapeutic Strategies for Translational Applications
International Journal of Molecular Sciences · 15.10.2023 · 24 (20) · 15206
DOI: 10.3390/ijms242015206 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 15.10.2023. Verfasst von Jessica N Ziegler und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, KY 40536, USA. Hauptthemen laut MEDLINE: Extracellular Vesicles, Neoplasms. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Institution of Health, American Heart Association (AHA) Career Development.
Abstract (Originalsprache)
Extracellular vesicles (EVs) are small, membrane-bound vesicles used by cells to deliver biological cargo such as proteins, mRNA, and other biomolecules from one cell to another, thus inducing a specific response in the target cell and are a powerful method of cell to cell and organ to organ communication, especially during the pathogenesis of human disease. Thus, EVs may be utilized as prognostic and diagnostic biomarkers, but they also hold therapeutic potential just as mesenchymal stem cells have been used in therapeutics. However, unmodified EVs exhibit poor targeting efficacy, leading to the necessity of engineered EVS. To highlight the advantages and therapeutic promises of engineered EVs, in this review, we summarized the research progress on engineered EVs in the past ten years, especially in the past five years, and highlighted their potential applications in therapeutic development for human diseases. Compared to the existing stem cell-derived EV-based therapeutic strategies, engineered EVs show greater promise in clinical applications: First, engineered EVs mediate good targeting efficacy by exhibiting a targeting peptide that allows them to specifically target a specific organ or even cell type, thus avoiding accumulation in undesired locations and increasing the potency of the treatment. Second, engineered EVs can be artificially pre-loaded with any necessary biomolecular cargo or even therapeutic drugs to treat a variety of human diseases such as cancers, neurological diseases, and cardiovascular ailments. Further research is necessary to improve logistical challenges in large-scale engineered EV manufacturing, but current developments in engineered EVs prove promising to greatly improve therapeutic treatment for traditionally difficult to treat diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, KY 40536, USA.
ORCID-Profile: Changhai Tian
Förderung
- NHLBI NIH HHS
- National Institution of Health
- American Heart Association (AHA) Career Development
Zitieren
APA
Ziegler, J. N., & Tian, C. (2023). Engineered Extracellular Vesicles: Emerging Therapeutic Strategies for Translational Applications. International Journal of Molecular Sciences, 24(20), 15206. https://doi.org/10.3390/ijms242015206
Vancouver
Ziegler JN, Tian C. Engineered Extracellular Vesicles: Emerging Therapeutic Strategies for Translational Applications. International Journal of Molecular Sciences. 2023;24(20):15206. doi:10.3390/ijms242015206
BibTeX
@article{Ziegler2023,
author = {Ziegler, Jessica N and Tian, Changhai},
title = {Engineered Extracellular Vesicles: Emerging Therapeutic Strategies for Translational Applications},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {20},
pages = {15206},
doi = {10.3390/ijms242015206}
}
EUVIMED